FDA clears Novo Nordisk's insulin injection pen for children

NovoPen Echo--Courtesy of Novo Nordisk

Novo Nordisk ($NVO) landed FDA clearance for its insulin injection pen that allows for fine dose adjustments and includes a memory function to record the time since a patient's last injection. The company developed its NovoPen Echo specifically for children, incorporating simple functionality with a sleek, colorful design. The U.S. agency's 510(k) clearance will help the Echo reach Novo's intended launch goal of early 2014--the device is already available in Europe, Canada and Israel. Release

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…